Drugs & Aging

, Volume 10, Issue 6, pp 421–434 | Cite as

Angiotensin II Receptor Antagonists

Potential in Elderly Patients with Cardiovascular Disease
  • Louise M. BurrellEmail author
  • Colin I. Johnston
Review Article Drug Therapy


Raised blood pressure in the elderly is not a normal consequences of aging, but is a major risk factor for cardiovascular disease. Cardiac and cerebrovascular disease account for >50% of deaths among people aged >65 years. Because the percentage of elderly people in most populations is rising, blood pressure control in this group is becoming increasingly important. Several large intervention studies in the elderly have demonstrated that antihypertensive medication reduces cardiovascular morbidity and mortality. In addition, the absolute benefits of blood pressure reduction are higher in elderly compared with younger patients.

ACE inhibitors are effective and well tolerated in the treatment of hypertension in the elderly. Their success led to interest in alternative ways of blocking the renin angiotensin syste, and the subsequent development of angiotensin II (AII) receptor antagonists. Losartan was the first drug in this class to become commercially available. Since then, valsartan has been launched in some markets and others are likely to be launched in the near future. Losartan is effective in the treatment of essential hypertension and has a low incidence of adverse effects. First-dose hypotension is very uncommon and, at the present time, cough does not appear to be an adverse effect of these drugs, although long term tolerability studies are needed to confirm this. Angioedema, a rare but life-threatening adverse effect of ACE inhibitors, has also been associated with losartan. Current data suggest that All receptor antagonists are effective in elderly hypertensive patients, although further data are needed to confirm these findings.

At present, All receptor antagonists are likely to be used in hypertensive patients who are intolerant of ACE inhibitors, although this may change with the availability of long term tolerability and clinical outcomes data.


Angiotensin Converting Enzyme Enalapril Losartan Angiotensin Converting Enzyme Inhibitor Felodipine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    World Health Organization. Hypertension control. Geneva: WHO, 1996Google Scholar
  2. 2.
    Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; I: 1349–54CrossRefGoogle Scholar
  3. 3.
    MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–12CrossRefGoogle Scholar
  4. 4.
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255–64CrossRefGoogle Scholar
  5. 5.
    Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). Lancet 1991; 338: 1281–5PubMedCrossRefGoogle Scholar
  6. 6.
    Johannesson M, Dahlof B, Lindholm LH, et al. The cost-effectiveness of treating hypertension in elderly people — an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). J Intern Med 1993; 234: 317–23PubMedCrossRefGoogle Scholar
  7. 7.
    National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in the elderly. Hypertension 1994; 23: 275–85CrossRefGoogle Scholar
  8. 8.
    Byyny RL. Hypertension in the elderly. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. New York: Raven Press, 1995: 227–51Google Scholar
  9. 9.
    Abdelrahman AM, Burrell LM, Johnston CI. Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone. J Hypertens 1993; 11 Suppl. 3: S23–6Google Scholar
  10. 10.
    Johnston CI, Burrell LM. Evolution of blockade of the renin-angiotensin system. J Hum Hypertens 1995; 9: 375–80PubMedGoogle Scholar
  11. 11.
    The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe heart failure. N Engl J Med 1987: 316: 1429–35CrossRefGoogle Scholar
  12. 12.
    The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–91CrossRefGoogle Scholar
  13. 13.
    GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. Lancet 1994; 343: 1115–22Google Scholar
  14. 14.
    The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors with heart failure. Lancet 1993; 342: 821–8Google Scholar
  15. 15.
    Burrell LM, Johnston CI. Beyond ACE inhibition: new developments in drug therapy for hypertension. Med J Aust 1995; 162: 659–61PubMedGoogle Scholar
  16. 16.
    Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403–7PubMedCrossRefGoogle Scholar
  17. 17.
    Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists. Arch Intern Med 1995; 155: 1361–8PubMedCrossRefGoogle Scholar
  18. 18.
    Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205–51PubMedGoogle Scholar
  19. 19.
    Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am JCardiol 1995; 75: 793–5CrossRefGoogle Scholar
  20. 20.
    Israili ZH, Hall WD. ACE inhibitors: differential use in elderly patients with hypertension. Drugs Aging 1995; 7: 355–71PubMedCrossRefGoogle Scholar
  21. 21.
    Chan JC, Critchley JA, Lappe JT, et al. Randomised, doubleblind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens 1995; 9: 765–71PubMedGoogle Scholar
  22. 22.
    Nagano M, Higaki J, Mikami H, et al. Role of the renin-angiotensin system in hypertension in the elderly. Blood Press Suppl 1994; 5: 130–3PubMedGoogle Scholar
  23. 23.
    Grossman E, Peleg E, Carroll J, et al. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 1994; 7: 1041–4PubMedGoogle Scholar
  24. 24.
    Nolan L, O’Malley K. Prescribing for the elderly, part 1: sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc 1988; 36: 142–9PubMedGoogle Scholar
  25. 25.
    Lo M-W, Goldberg MR, McCrea JB, et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995; 58: 611–9CrossRefGoogle Scholar
  26. 26.
    Ogihara T, Nagano M, Mikami H, et al. Effects of the angiotensin II receptor antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects. Clin Ther 1994; 16: 74–86PubMedGoogle Scholar
  27. 27.
    Holwerda NJ, Fogari R, Angeli P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14: 1147–51PubMedCrossRefGoogle Scholar
  28. 28.
    Stearns RA, Chakravarty PK, Chen R, et al. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995; 23(2): 207–15PubMedGoogle Scholar
  29. 29.
    Pitt B, Chang P, Timmermans PB. Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Cardiovasc Drugs Ther 1995; 9: 693–700PubMedCrossRefGoogle Scholar
  30. 30.
    Shand BI, Gilchrist NL, Nicholls MG, et al. Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: a pilot study. J Hum Hypertens 1995; 9: 233–5PubMedGoogle Scholar
  31. 31.
    Weber MA, Byyny RL, Pratt JH, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 1995; 155: 405–11PubMedCrossRefGoogle Scholar
  32. 32.
    Tsunoda K, Abe K, Hagino T, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993; 6: 28–32PubMedGoogle Scholar
  33. 33.
    Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345–50PubMedCrossRefGoogle Scholar
  34. 34.
    Tikkanen I, Omvik P, Jensen H. Comparison of the angiotensin II antagonist, losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13: 1343–51PubMedCrossRefGoogle Scholar
  35. 35.
    Mallion J-M, Bradstreet DC, Makris L, et al. Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate hypertension. J Hypertens 1995; 13 Suppl. 1: S35–41CrossRefGoogle Scholar
  36. 36.
    Dahlof B, Keller SE, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995; 8: 578–83PubMedCrossRefGoogle Scholar
  37. 37.
    MacKay JH, Arcuri KE, Goldberg AI, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension: a double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278–85PubMedCrossRefGoogle Scholar
  38. 38.
    Soffer BA, Wright Jr JT, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112–7PubMedCrossRefGoogle Scholar
  39. 39.
    Weir MR, Elkins M, Liss C, et al. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther 1996; 18(3): 1–18CrossRefGoogle Scholar
  40. 40.
    Ogihara T, Arakawa K, Iimura O, et al. Open clinical studies on a new angiotensin II receptor antagonist, TCV 116. J Hypertens 1994; 12: Suppl.: S35–8Google Scholar
  41. 41.
    van den Meiracker AH, Admiraal PJ, Janssen JA, et al. Hemodynamic and biochemical effects of the AT 1 receptor antagonist irbesartan in hypertension. Hypertension 1995; 25: 22–9PubMedCrossRefGoogle Scholar
  42. 42.
    Dunlay MC, Fitzpatrick V, Chrysant S, et al. Losartan potassium as initial therapy in patients with severe hypertension. J Hum Hypertens 1995; 9: 861–7PubMedGoogle Scholar
  43. 43.
    Ruff D, Gazdick LP, Berman R, et al. Comparative effects of combination therapy with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. J Hypertens 1996; 14: 263–70PubMedCrossRefGoogle Scholar
  44. 44.
    Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88: 1602–9PubMedCrossRefGoogle Scholar
  45. 45.
    Crozier I, Ikram H, Awan N, et al. Losartan in heart failure: hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. Circulation 1995; 91(3): 691–7PubMedCrossRefGoogle Scholar
  46. 46.
    Dickstein K, Gottlieb S, Fleck E, et al. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. J Hypertens 1994; 12 Suppl.: S31–5Google Scholar
  47. 47.
    Burrell LM. Risk-benefit assessment of losartan potassium in the treatment of hypertension. Drug Saf 1997; 16(1): 56–65PubMedCrossRefGoogle Scholar
  48. 48.
    Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996; 51(5): 820–45PubMedCrossRefGoogle Scholar
  49. 49.
    Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456–62PubMedCrossRefGoogle Scholar
  50. 50.
    Burnier M, Rutschmann B, Nussberger J. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993; 22: 339–47PubMedCrossRefGoogle Scholar
  51. 51.
    Gansevoort RT, de Zeeuw D, Shahinfar S, et al. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994; 12 Suppl. 2: S37–42Google Scholar
  52. 52.
    Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861–7PubMedCrossRefGoogle Scholar
  53. 53.
    Kawabata M, Takabatake T, Ohta H, et al. Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension. Blood Press Suppl 1994; 5: 117–21PubMedGoogle Scholar
  54. 54.
    Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129–38PubMedGoogle Scholar
  55. 55.
    Ichikawa I. Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int 1996; 50: 684–92PubMedCrossRefGoogle Scholar
  56. 56.
    Lacourciere Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group. J Hypertens 1994; 12: 1387–93PubMedGoogle Scholar
  57. 57.
    Acker CG, Greenberg A. Angioedema induced by the angiotensin II blocker losartan [letter]. N Engl J Med 1995; 333: 1572PubMedCrossRefGoogle Scholar
  58. 58.
    Schlienger RG, Saxer M, Haefeli W. Reversible ageusia associated with losartan. Lancet 1996; 347: 471–2PubMedCrossRefGoogle Scholar
  59. 59.
    Sweet CS, Bradstreet DC, Berman RS, et al. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7: 1035–40PubMedGoogle Scholar
  60. 60.
    Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995; 25: 37–46PubMedCrossRefGoogle Scholar
  61. 61.
    Moan A, Risanger T, Eide I, et al. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 1994; 3(3): 185–8PubMedCrossRefGoogle Scholar
  62. 62.
    Saine DR, Ahrens ER. Renal impairment associated with losartan [letter]. Ann Intern Med 1996; 124(8): 775PubMedGoogle Scholar
  63. 63.
    Kjeldsen SE, Omvik P. Losartan and the LIFE-study: antihypertensive treatment with ATI-receptor antagonist. Tidsskr Nor Laegeforen 1996; 116: 504–7PubMedGoogle Scholar
  64. 64.
    Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91: 1269–81PubMedCrossRefGoogle Scholar
  65. 65.
    Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–52PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  1. 1.Department of MedicineUniversity of Melbourne, Austin and Repatriation Medical CentreHeidelbergAustralia

Personalised recommendations